BridgeBio Oncology Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: BridgeBio Oncology Therapeutics Inc.
Former names: Helix Acquisition Corp. II
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: South SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: BBOT
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001869105

Board of directors

Follow this board

Albert A. Holman III · Director
Since 2025
Bihua Chen · Director · CEO and Chairperson Overboarded
Since 2024
Eli M. Wallace · Director · Chief Executive Officer
Since 2025
Frank Mccormick · Director
Since 2025
Jake Bauer · Director
Since 2025
John P. Schmid · Director Overboarded
Since 2024
Mark C. McKenna · Director Overboarded
Since 2024
Michelle Doig · Director
Since 2025
Neil Kumar · Director
Since 2025
Pedro Beltran · Director · President and CEO
Since 2026
Peter F. Lebowitz · Director
Since 2026
Praveen P. Tipirneni · Director
Since 2025
Raymond J. Kelleher · Director
Since 2025

Chief executives

Pedro Beltran · President and CEO

Dates unknown

Eli M. Wallace · Chief Executive Officer

Since August 2025

Bihua Chen · CEO and Chairperson

2024 – 2025 · Former

Director election results

Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Peter F. Lebowitz

100.0%

Board connections

7 of this board's directors also sit on 17 other boards. 15 are in the same sector.

Shared director Other board Same sector +1 more in the list below

Helix Acquisition Corp. III
via Bihua Chen, John P. Schmid and Mark C. McKenna
BlossomHill Therapeutics Inc. Same sector
via Bihua Chen and John P. Schmid
BridgeBio Pharma Inc. Same sector
via Frank Mccormick and Neil Kumar
AnaptysBio Inc. Same sector
via John P. Schmid
Biomea Fusion Inc. Same sector
via Bihua Chen
Design Therapeutics Inc. Same sector
via John P. Schmid
Enliven Therapeutics Inc. Same sector
via Jake Bauer
Erasca Inc. Same sector
via Bihua Chen
First Tracks Biotherapeutics Inc. Same sector
via John P. Schmid
Freenome Inc. Same sector
via Mark C. McKenna
Immunovant Inc. Same sector
via Jake Bauer
Maze Therapeutics Inc. Same sector
via Neil Kumar
NewAmsterdam Pharma Company N.V. Same sector
via Mark C. McKenna
Spyre Therapeutics Inc. Same sector
via Mark C. McKenna
TCGX Acquisition Corp. II
via Mark C. McKenna
Tectonic Therapeutic Inc. Same sector
via Praveen P. Tipirneni
Xeris Biopharma Holdings Inc. Same sector
via John P. Schmid

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 21, 2026	Cobo Marc Officer (Principal Accounting Officer)	Shares withheld for tax	−203	$2.68	$544
Oct 1, 2026	Pedro Beltran Director, Officer (President and CEO)	Shares withheld for tax	−1,047	$3.94	$4,125
Oct 1, 2026	Yong Ben Officer (Chief Med & Dev Officer)	Shares withheld for tax	−1,047	$3.94	$4,125
Oct 1, 2026	Elmelech Idan Officer (COO & Principal Financial Ofcr)	Shares withheld for tax	−343	$3.94	$1,351
Oct 1, 2026	Cobo Marc Officer (Principal Accounting Officer)	Shares withheld for tax	−126	$3.94	$496
Sep 10, 2026	Cobo Marc Officer (Principal Accounting Officer)	Grant or award	+9,038	—	—
Sep 10, 2026	Cobo Marc Officer (Principal Accounting Officer)	Shares withheld for tax	−203	$5.52	$1,121
Jul 1, 2026	Pedro Beltran Director, Officer (President and CEO)	Shares withheld for tax	−1,047	$7.80	$8,167
Jul 1, 2026	Yong Ben Officer (Chief Med & Dev Officer)	Shares withheld for tax	−1,047	$7.80	$8,167
Jul 1, 2026	Elmelech Idan Officer (COO & Principal Financial Ofcr)	Shares withheld for tax	−343	$7.80	$2,675
Jul 1, 2026	Cobo Marc Officer (Principal Accounting Officer)	Shares withheld for tax	−125	$7.80	$975
Jul 1, 2026	Bihua Chen Director, 10% owner	Other	−4,528,186	—	—
Jul 1, 2026	Bihua Chen Director, 10% owner	Other	+2,692,459	—	—
Jul 1, 2026	Bihua Chen Director, 10% owner	Other	+1,704,862	—	—
Jul 1, 2026	Bihua Chen Director, 10% owner	Other	+130,865	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about BridgeBio Oncology Therapeutics Inc.

Who is the CEO of BridgeBio Oncology Therapeutics Inc.?

Eli M. Wallace has been BridgeBio Oncology Therapeutics Inc.'s Chief Executive Officer since August 2025.

How many directors are on BridgeBio Oncology Therapeutics Inc.'s board?

BridgeBio Oncology Therapeutics Inc.'s board has 13 directors: Albert A. Holman III, Bihua Chen, Eli M. Wallace, Frank Mccormick, Jake Bauer, John P. Schmid, Mark C. McKenna, Michelle Doig, Neil Kumar, Pedro Beltran and 3 others.

How is BridgeBio Oncology Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="bridgebio-oncology-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.